Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fulgent Genetics Inc (NQ: FLGT )

20.53 +0.06 (+0.29%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Fulgent Genetics Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
Fulgent Reports Second Quarter 2024 Financial Results
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent to Announce Second Quarter 2024 Financial Results on Friday, August 2, 2024
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Data at ASCO 2024 Highlights Antitumor Activity from Lead Therapeutic Oncology Candidate, FID-007, in Head and Neck Cancer
From Fulgent Pharma
Via Business Wire
Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2024 Annual Meeting
From Fulgent Pharma
Via Business Wire
Earnings Preview: Fulgent Genetics
Via Benzinga
Why Is Fulgent Genetics Stock Moving Higher Today?
Fulgent Genetics Inc (NASDAQ: FLGT) reported Q2 sales of $68 million, beating the consensus estimate of $62.68 million.< 
Via Benzinga
Moffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer Therapeutics
From Fulgent Pharma
Via Business Wire
FLGT Stock Earnings: Fulgent Genetics Beats EPS, Misses Revenue for Q1 2024
FLGT stock results show that Fulgent Genetics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Fulgent Reports First Quarter 2024 Financial Results
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Genetics to Announce First Quarter 2024 Financial Results on Friday, May 3, 2024
From Fulgent Genetics, Inc.
Via Business Wire
Earnings Outlook For Fulgent Genetics
Via Benzinga
Fulgent Genetics Earnings Perspective: Return On Capital Employed
Via Benzinga
Fulgent Reports Fourth Quarter and Full Year 2023 Financial Results
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Genetics to Announce Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 28, 2024
From Fulgent Genetics, Inc.
Via Business Wire
The 3 Best Digital Health Stocks for Personalized Medicine
Digital health stocks are becoming increasingly relevant as more and more people seek greater control over their health. 
Via InvestorPlace
Fulgent to Participate in the Piper Sandler 35th Annual Healthcare Conference
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Shares Data from Two Poster Presentations at SITC 2023 Annual Meeting
From Fulgent Genetics, Inc.
Via Business Wire
Earnings Scheduled For November 3, 2023
Companies Reporting Before The Bell • Arcutis Biotherapeutics (NASDAQ:ARQT) is expected to report quarterly loss at $0.86 per share on revenue of $32.83 million. 
Via Benzinga
Fulgent Reports Third Quarter 2023 Financial Results
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Announces Two Poster Presentations at SITC 2023 Annual Meeting
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Genetics to Announce Third Quarter 2023 Financial Results on Friday November 3, 2023
From Fulgent Genetics, Inc.
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Fulgent Reports Second Quarter 2023 Financial Results
From Fulgent Genetics, Inc.
Via Business Wire
Earnings Scheduled For August 4, 2023
Companies Reporting Before The Bell • WPP (NYSE:WPP) is projected to report earnings for its first quarter. • Anglogold Ashanti (NYSE:AU) is likely to report earnings for its first quarter. 
Via Benzinga
Exagen Inc. Appoints Paul Kim to Board of Directors
From Exagen Inc.
Via GlobeNewswire
Fulgent Genetics to Announce Second Quarter 2023 Financial Results on Friday, August 4, 2023
From Fulgent Genetics, Inc.
Via Business Wire
Got $2,500? This Dirt Cheap Growth Stock Could Be Worth Buying Hand Over Fist
Fulgent is moving past its pandemic-era business, and that's a good thing. 
Via The Motley Fool
Fulgent Data at ASCO 2023 Highlights Progress for Its Lead Therapeutic Oncology Candidate, FID-007, in Various Cancers
From Fulgent Genetics, Inc.
Via Business Wire
Better Diversified Biotech Stock: 23andMe vs. Fulgent Genetics
Neither has a traditional business model, but that could be an asset for both. 
Via The Motley Fool
2 Undervalued Stocks to Buy for Potentially Massive Gains in the Next 10 Years
Both are experiencing a bit of a hangover from declining COVID-19-related sales. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.